Purchase this article with an account.
D. Moreno-Paramo, A. Perez-Montesinos, R. Velez-Montoya, M. Martinez-Castellanos, G. Garcia-Aguirre, J. Dalma-Weiszhausz, J. Jimenez-Sierra, H. Quiroz-Mercado, D. Ochoa-Contreras, V. Morales-Canton; Complications After Intravitreal Bevacizumab (Avastin): Analysis of 5132 Injections. Invest. Ophthalmol. Vis. Sci. 2009;50(13):45.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess the ocular and systemic complications after intravitreal injection of 2.5mg of Bevacizumab (Avastin).
We retrospectively reviewed 5132 cases of intravitreal injections of Bevacizumab (Avastin), 2.5 mg/0.1 ml within a 3 year period in the Retina Service of Asociación para Evitar la Ceguera en Mexico.
Six eyes (0.11%) with proliferative diabetic retinopathy developed tractional retinal detachment. Seven eyes (0.13%) developed infectious endophtalmitis; one eye presented a rhegmatogenuos retinal detachment (0.01%), 3 vitreous hemorrhage (0.05%) and leakage of vitreous in 3 patients (0.05%).
Intravitreal injection of bevacizumab seems to be a low risk procedure with a minimal rate of ocular complications.
This PDF is available to Subscribers Only